{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T12:06:46Z","timestamp":1779883606937,"version":"3.53.1"},"reference-count":44,"publisher":"Elsevier BV","issue":"8-9","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100004726","name":"Ministry of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004726","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.neurol.2016.07.012","type":"journal-article","created":{"date-parts":[[2016,8,24]],"date-time":"2016-08-24T12:04:56Z","timestamp":1472040296000},"page":"423-432","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Guidelines for clinical pharmacological practices in Huntington's disease"],"prefix":"10.1016","volume":"172","author":[{"given":"G.","family":"D\u00e9sam\u00e9ricq","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Youssov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Saleh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Sherer-Gagou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Verny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Bachoud-L\u00e9vi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neurol.2016.07.012_bib0235","first-page":"CD006456","article-title":"Therapeutic interventions for symptomatic treatment in Huntington's disease","author":"Mestre","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.neurol.2016.07.012_bib0240","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1474-4422(10)70245-3","article-title":"Huntington's disease: from molecular pathogenesis to clinical treatment","volume":"10","author":"Ross","year":"2011","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0245","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1002\/mds.23953","article-title":"Pharmacologic approaches to the treatment of Huntington's disease","volume":"27","author":"Venuto","year":"2012","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0250","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1002\/mds.26014","article-title":"Current therapeutic options for Huntington's disease: good clinical practice versus evidence-based approaches?","volume":"29","author":"Killoran","year":"2014","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0255","doi-asserted-by":"crossref","first-page":"1788","DOI":"10.1002\/mds.22188","article-title":"A Europe-wide assessment of current medication choices in Huntington's disease","volume":"23","author":"Priller","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0260","first-page":"3","article-title":"An international survey-based algorithm for the pharmacologic treatment of chorea in Huntington's disease","author":"Burgunder","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.neurol.2016.07.012_bib0265","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1212\/01.wnl.0000198586.85250.13","article-title":"Tetrabenazine as antichorea therapy in Huntington disease: a randomized controlled trial","volume":"66","author":"Huntington Study Group","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.07.012_bib0270","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1002\/ana.21181","article-title":"Riluzole in Huntington's disease: a 3-year, randomized controlled study","volume":"62","author":"Landwehrmeyer","year":"2007","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0275","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2217\/epi.14.19","article-title":"Epigenetic modifications as novel therapeutic targets for Huntington's disease","volume":"6","author":"Wang","year":"2014","journal-title":"Epigenomics"},{"key":"10.1016\/j.neurol.2016.07.012_bib0280","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/0303-8467(80)90017-7","article-title":"Seven cases of Huntington's disease in childhood and levodopa induced improvement in the hypokinetic\u00a0\u2013\u00a0rigid form","volume":"82","author":"Jongen","year":"1980","journal-title":"Clin Neurol Neurosurg"},{"key":"10.1016\/j.neurol.2016.07.012_bib0285","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1177\/08830738030180061301","article-title":"Unusual early-onset Huntington's disease","volume":"18","author":"Vargas","year":"2003","journal-title":"J Child Neurol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0290","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1002\/mds.21971","article-title":"The current clinical management of Huntington's disease","volume":"23","author":"Phillips","year":"2008","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0295","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/s00455-010-9302-4","article-title":"Dysphagia in Huntington's disease: a review","volume":"26","author":"Heemskerk","year":"2011","journal-title":"Dysphagia"},{"key":"10.1016\/j.neurol.2016.07.012_bib0300","doi-asserted-by":"crossref","first-page":"2701","DOI":"10.2174\/138161206777698693","article-title":"Pharmacological management of Huntington's disease: an evidence-based review","volume":"12","author":"Bonelli","year":"2006","journal-title":"Curr Pharm Des"},{"key":"10.1016\/j.neurol.2016.07.012_bib0305","first-page":"181","article-title":"Symptomatic treatment of Huntington disease","volume":"5","author":"Adam","year":"2008","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"10.1016\/j.neurol.2016.07.012_bib0310","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1002\/mds.870090609","article-title":"Cortical myoclonus in Huntington's disease","volume":"9","author":"Thompson","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0315","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1097\/00002826-200209000-00007","article-title":"Olanzapine for Huntington's disease: an open label study","volume":"25","author":"Bonelli","year":"2002","journal-title":"Clin Neuropharmacol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0320","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.parkreldis.2012.04.029","article-title":"Effect of tetrabenazine on computerized dynamic posturography in Huntington disease patients","volume":"18","author":"Fekete","year":"2012","journal-title":"Parkinsonism Relat Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0325","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1002\/1531-8257(200001)15:1<171::AID-MDS1031>3.0.CO;2-Y","article-title":"Bruxism in Huntington's disease","volume":"15","author":"Tan","year":"2000","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0330","doi-asserted-by":"crossref","DOI":"10.1176\/jnp.16.3.381-a","article-title":"Treatment of bruxism in Huntington's disease with botulinum toxin","volume":"16","author":"Nash","year":"2004","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.neurol.2016.07.012_bib0335","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1177\/0269881103174009","article-title":"Ziprasidone in Huntington's disease: the first case reports","volume":"17","author":"Bonelli","year":"2003","journal-title":"J Psychopharmacol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0340","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/S0140-6736(74)92338-1","article-title":"A double-blind trial of tetrabenazine, thiopropazate, and placebo in patients with chorea","volume":"303","author":"Mclellan","year":"1974","journal-title":"Lancet"},{"key":"10.1016\/j.neurol.2016.07.012_bib0345","first-page":"1","article-title":"Aripiprazole in the treatment of Huntington's disease: a case series","volume":"5","author":"Ciammola","year":"2009","journal-title":"Neuropsychiatr Dis Treat"},{"key":"10.1016\/j.neurol.2016.07.012_bib0350","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/YIC.0b013e3283348018","article-title":"Combating depression in Huntington's disease: effective antidepressive treatment with venlafaxine XR","volume":"25","author":"Holl","year":"2010","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0355","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1176\/ajp.118.1.79","article-title":"Effect of imipramine (tofranil) on depression and hyperkinesia in Huntington's disease","volume":"118","author":"Whittier","year":"1961","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.012_bib0360","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1097\/00004714-200208000-00020","article-title":"Rapid onset of tardive dyskinesia in Huntington disease with olanzapine","volume":"22","author":"Benazzi","year":"2002","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0365","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1097\/YIC.0b013e3283407775","article-title":"Risperidone long-acting injection and Huntington's disease: case series with significant psychiatric and behavioural symptoms","volume":"26","author":"Johnston","year":"2011","journal-title":"Int Clin Psychopharmacol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0370","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1159\/000327754","article-title":"Suicidal behavior in prodromal Huntington disease","volume":"8","author":"Fiedorowicz","year":"2011","journal-title":"Neurodegener Dis"},{"key":"10.1016\/j.neurol.2016.07.012_bib0375","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1345\/aph.1C352","article-title":"Mirtazapine in suicidal Huntington's disease","volume":"37","author":"Bonelli","year":"2003","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.neurol.2016.07.012_bib0380","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1176\/jnp.8.2.209","article-title":"ECT in genetically confirmed Huntington's disease","volume":"8","author":"Lewis","year":"1996","journal-title":"J Neuropsychiatry Clin Neurosci"},{"key":"10.1016\/j.neurol.2016.07.012_bib0385","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3109\/10401239609149087","article-title":"L-Deprenyl augmentation of fluoxetine in a patient with Huntington's disease","volume":"8","author":"Patel","year":"1996","journal-title":"Ann Clin Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.012_bib0390","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1080\/15622970701332520","article-title":"Lamotrigine in motor and mood symptoms of Huntington's disease","volume":"9","author":"Shen","year":"2008","journal-title":"World J Biol Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.012_bib0395","first-page":"3","article-title":"An international survey-based algorithm for the pharmacologic treatment of irritability in Huntington's disease","author":"Groves","year":"2011","journal-title":"PLoS Curr"},{"key":"10.1016\/j.neurol.2016.07.012_bib0400","doi-asserted-by":"crossref","first-page":"115","DOI":"10.3109\/00048677509159834","article-title":"A double blind trial of lithium carbonate and haloperidol in Huntington's chorea","volume":"9","author":"Leonard","year":"1975","journal-title":"Aust N Z J Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.012_bib0405","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1176\/appi.ajp.158.12.1966","article-title":"Successful multimodality treatment of severe behavioral disturbance in a patient with advanced Huntington's disease","volume":"158","author":"Blass","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.012_bib0410","first-page":"69","article-title":"Short-term effects of olanzapine in Huntington disease","volume":"14","author":"Squitieri","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0415","doi-asserted-by":"crossref","first-page":"1994","DOI":"10.1016\/j.pnpbp.2008.07.010","article-title":"Cyproterone for treatment of hypersexuality in an elderly Huntington's disease patient","volume":"32","author":"Tavares","year":"2008","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.neurol.2016.07.012_bib0420","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/mds.870090317","article-title":"Leuprolide acetate for exhibitionism in Huntington's disease","volume":"9","author":"Rich","year":"1994","journal-title":"Mov Disord"},{"key":"10.1016\/j.neurol.2016.07.012_bib0425","first-page":"216","article-title":"Obsessive compulsive disorder in huntington disease: a case of isolated obsessions successfully treated with sertraline","volume":"15","author":"Patzold","year":"2002","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0430","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1176\/appi.psy.47.1.70","article-title":"Quetiapine in the treatment of behavioral disturbances in patients with Huntington's disease","volume":"47","author":"Alpay","year":"2006","journal-title":"Psychosomatics"},{"key":"10.1016\/j.neurol.2016.07.012_bib0435","first-page":"219","article-title":"Behavioral changes in Huntington disease","volume":"14","author":"Craufurd","year":"2001","journal-title":"Neuropsychiatry Neuropsychol Behav Neurol"},{"key":"10.1016\/j.neurol.2016.07.012_bib0440","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1212\/WNL.54.2.452","article-title":"Rate of functional decline in Huntington's disease","volume":"54","author":"Marder","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2016.07.012_bib0445","first-page":"e131","article-title":"Hypersexual features in Huntington's disease","volume":"52","author":"Jhanjee","year":"2011","journal-title":"Singapore Med J"},{"key":"10.1016\/j.neurol.2016.07.012_bib0450","first-page":"55","article-title":"Efficiency of carbamazepine in the treatment of micturitional disturbances in Huntington disease","author":"Cochen","year":"2000","journal-title":"Neurology"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716300789?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0035378716300789?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2021,4,5]],"date-time":"2021-04-05T20:42:09Z","timestamp":1617655329000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0035378716300789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":44,"journal-issue":{"issue":"8-9","published-print":{"date-parts":[[2016,8]]}},"alternative-id":["S0035378716300789"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2016.07.012","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Guidelines for clinical pharmacological practices in Huntington's disease","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2016.07.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}